CN110960513A - Microsphere array and preparation method and application thereof - Google Patents
Microsphere array and preparation method and application thereof Download PDFInfo
- Publication number
- CN110960513A CN110960513A CN201911200094.6A CN201911200094A CN110960513A CN 110960513 A CN110960513 A CN 110960513A CN 201911200094 A CN201911200094 A CN 201911200094A CN 110960513 A CN110960513 A CN 110960513A
- Authority
- CN
- China
- Prior art keywords
- microspheres
- growth factor
- interleukin
- array
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a microsphere array, and relates to the technical field of biology. The skin repairing carrier comprises a carrier, wherein microspheres are carried on the carrier, bioactive factors are filled in the microspheres, and the bioactive factors are used for repairing skin. The invention also discloses a preparation method and application of the microsphere array. The microsphere array of the invention uses hyaluronic acid which is a material easily absorbed by human skin as a substrate to prepare microspheres, bioactive factors are loaded into the microspheres, and then the microsphere array is prepared.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a microsphere array and a preparation method and application thereof.
Background
The skin is a surface tissue covering the whole body, and can protect internal tissues and organs of the human body from being damaged, prevent water loss in the body, prevent harmful substances from invading the human body and the like. Therefore, the skin is an important component of the human body and more directly expresses the signs of human health and aging. When the skin is vigorous in metabolism, smooth in blood circulation and rich in nutrition, the skin is fine, smooth, tender and very elastic, and wrinkles and color spots are not easy to appear. Today, the skin of a person is affected by many adverse factors, such as: water quality, air pollution (especially PM2.5), excessive sunlight solarization, uneven diet, working pressure and the like, so various problems such as acne, freckles, summer spots, heat rash, bromhidrosis, sweat sores, water herpes and the like are always puzzled to people. The current various functional cosmetics have a little curative effect, but cannot meet the perfect and innocent pursuit of people for skin.
However, in the current market, the following problems still exist in the conventional skin care products or medicines for repairing skin through survey feedback: (1) the improvement effect on skin problems such as laxity, darkness, acne, freckle, wrinkle and the like is poor; (2) the skin care product has low absorption and utilization rate.
Disclosure of Invention
In view of the above problems in the prior art, the present application provides a microsphere array to solve the above problems in the prior art. The invention also provides a preparation method and application of the microsphere array.
The technical scheme of the invention is as follows:
a microsphere array comprises a carrier, wherein the carrier is provided with microspheres, bioactive factors are filled in the microspheres, and the bioactive factors are used for repairing skin.
Wherein the microspheres are distributed and arranged on the carrier in a random or ordered form.
Wherein the bioactive factor is EGF, basic fibroblast growth factor, transforming growth factor- β, platelet derived growth factor, interleukin 2 and interleukin 10.
EGF is also called epidermal growth factor, and has a structure consisting of 53 amino acids, a molecular weight of 6201 daltons, and disulfide bonds consisting of 6 cysteines in a molecule to form 3 intramolecular cyclic structures, which constitute a receptor binding region necessary for biological activity. Numerous experimental studies have shown that EGF stimulates the proliferation of a variety of cells, mainly epidermal and endothelial cells. The skin-care product has good curative effect on repairing and healing wound surfaces of corneal injury, burns, scalds, operations and the like, and can stimulate the synthesis and secretion of some extracellular macromolecules (such as hyaluronic acid, collagen and the like) and moisten the skin, thereby being a key factor for determining the vitality and health of the skin. The discovery of EGF reveals the mystery of human skin aging, which is the first recognition that skin aging can be reversed and the skin can become younger again.
Basic fibroblast growth factor is a polypeptide that transmits developmental signals that promote the division of mesodermal and neuroectodermal cells. Has strong angiogenesis effect. In vitro, it can stimulate cell proliferation and migration, induce plasminogen activator and collagenase activity, and promote wound healing and cell renewal.
Transforming growth factor- β (transforming growth factor- β - β) belongs to a group of newly discovered TGF- β super family that regulates cell growth and differentiation.
Platelet-derived growth factor (PDGF), a common peptide regulator that stimulates connective tissue proliferation, is synthesized by bone marrow macrophages and stored in platelet Q granules. PDGF is a basic glycoprotein having a molecular weight of 28-35 kD and is a dimer of two polypeptide chains composed of two subunits (A chain and B chain) bonded to each other via a disulfide bond. PDGF is an important mitogen, can stimulate the division and proliferation of a plurality of cells such as vascular smooth muscle cells, fibroblasts, glial cells and the like, has the regulation effect on ontogenesis and cell differentiation, has prominent effect in wound healing, can promote angiogenesis and ensure skin nutrition.
Interleukin 2(Interleukin-2) is a polypeptide produced by T helper cells. Consists of 133 amino acids. Can be secreted by virus and toxin. Mainly promotes the proliferation of killer T cells and LAK cells.
Interleukin 10 inhibits cytokine production by activated T cells, and has been called cytokine synthesis inhibitor (csif), and in particular inhibits cytokines such as IL-2, IFN-. gamma.and lt produced by TH1 cells, thereby inhibiting the cellular immune response. It can be used in combination with interleukin 2 to improve skin immunity, and has antibacterial and anti-inflammatory effects.
Preferably, the percentage content ratio of EGF, basic fibroblast growth factor, transforming growth factor- β, platelet derived growth factor, interleukin 2 and interleukin 10 is 35:25:17:19:2: 2.
Furthermore, the particle size of the microsphere is 5-15 μm.
Preferably, the concentration of said microspheres on the carrier is 50000-100000/cm2。
Preferably, the carrier is a non-woven fabric.
The invention also provides a method for preparing the microsphere array, wherein the microspheres are fixed on the surface of the carrier through physical action.
The microsphere is prepared by the following method:
(1) dissolving hyaluronic acid in water to obtain 5-9% solution;
(2) adding polyethylene glycol, glycerol and tween 80 into the solution in the step (1) under the condition of stirring, wherein the volume percentage of the polyethylene glycol, the glycerol and the tween 80 is 45:35:25, and uniformly mixing;
(3) spray drying to obtain microsphere with particle diameter of 5-15 μm;
(4) and (3) adding the mixed aqueous solution of the EGF, the basic fibroblast growth factor, the transforming growth factor- β, the platelet-derived growth factor, the interleukin 2 and the interleukin 10 which are obtained in proportion into the microspheres prepared in the step (3), and quickly stirring the microspheres at the stirring speed of 800-1200 rpm.
The application also provides an application of the microsphere array in preparation of medicines or skin care products for repairing skin.
The beneficial technical effects of the invention are as follows: the microsphere array of the invention uses hyaluronic acid which is a material easily absorbed by human skin as a substrate to prepare microspheres, bioactive factors are loaded in the microspheres, and then the microsphere array is prepared.
Detailed Description
The present invention will be described in detail with reference to specific examples. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
(1) EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 with the weight percentage of 35:25:17:19:2:2 are dissolved in sterile water and are stirred uniformly for later use.
(1) Preparing microspheres: dissolving hyaluronic acid in water, adding polyethylene glycol, glycerol and tween 80 under stirring, wherein the concentration of hyaluronic acid is 5%, and the volume percentage of polyethylene glycol, glycerol and tween 80 is 45:35:25, and after uniformly mixing, spray drying to obtain microspheres with the particle size of 5 microns.
(2) Adding the mixed sterile aqueous solution of EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 obtained according to the proportion into the microspheres, and rapidly stirring under the condition of 800rmp to prepare the microspheres loaded with the bioactive factors.
(3) Treating the surface of the nonwoven fabric, which surface may be modified to provide physical forces, such as electrostatic, magnetic, compressive, and adhesive forces, etc., that allow the microspheres to adhere to such modified surface; it may also be a modified surface comprising a regular or irregular three-dimensional structure, such as micro-pores or grooves, which may be used to fix the microspheres on the surface by embedding them in the pores; microspheres may also be immobilized in a two-dimensional plane by allowing the microspheres to flow through a defined space, e.g. a tube, a chamber, which allows the microspheres to assemble into a two-dimensional array, wherein the concentration of microspheres on the nonwoven is 50000/cm2Forming an array of microspheres.
Example 2:
(1) EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 with the weight percentage of 35:25:17:19:2:2 are dissolved in sterile water and are stirred uniformly for later use.
(2) Preparing microspheres: dissolving hyaluronic acid in water, adding polyethylene glycol, glycerol and tween 80 under stirring, wherein the concentration of hyaluronic acid is 7%, and the volume percentage of polyethylene glycol, glycerol and tween 80 is 45:35:25, and after uniformly mixing, spray drying to obtain microspheres with the particle size of 10 microns.
(3) Adding the mixed sterile aqueous solution of EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 obtained according to the proportion into the microspheres, and rapidly stirring under the condition of 1000rmp to prepare the microspheres loaded with the bioactive factors.
(4) Treating the surface of the nonwoven fabric, which surface may be modified to provide physical forces, such as electrostatic, magnetic, compressive, and adhesive forces, etc., that allow the microspheres to adhere to such modified surface; it may also be a modified surface comprising a regular or irregular three-dimensional structure, such as micro-pores or grooves, which may be used to fix the microspheres on the surface by embedding them in the pores; microspheres may also be immobilized in a two-dimensional plane by allowing the microspheres to flow through a defined space, e.g. a tube, a chamber, which allows the microspheres to assemble into a two-dimensional array, wherein the concentration of microspheres on the nonwoven is 75000/cm2Forming an array of microspheres.
Example 3:
(1) EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 with the weight percentage of 35:25:17:19:2:2 are dissolved in sterile water and are stirred uniformly for later use.
(2) Preparing microspheres: dissolving hyaluronic acid in water, adding polyethylene glycol, glycerol and tween 80 under stirring, wherein the concentration of hyaluronic acid is 9%, and the volume percentage of polyethylene glycol, glycerol and tween 80 is 45:35:25, and after uniformly mixing, spray drying to obtain microspheres with the particle size of 15 microns.
(3) Adding the mixed sterile aqueous solution of EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 obtained according to the proportion into the microspheres, and rapidly stirring under the condition of 1200rmp to prepare the microspheres loaded with the bioactive factors.
(5) Watch with non-woven fabricA surface that may be modified to provide physical forces such as electrostatic, magnetic, compressive, and adhesive forces, etc., that allow the microspheres to adhere to such modified surface; it may also be a modified surface comprising a regular or irregular three-dimensional structure, such as micro-pores or grooves, which may be used to fix the microspheres on the surface by embedding them in the pores; microspheres may also be immobilized in a two-dimensional plane by allowing the microspheres to flow through a defined space, e.g. a tube, a chamber, which allows the microspheres to assemble into a two-dimensional array, wherein the concentration of microspheres on the nonwoven is 100000/cm2Forming an array of microspheres.
Use example:
selecting an object: 30 cases of 25-55 years old women with dry, loose, wrinkle, dark, acne, spot and closed skin are selected.
The experimental method comprises the following steps: after cleaning and repeating every morning and evening, the microsphere array prepared in the above example 2 is applied on the face of a patient for 15min, and then massaged until absorption, wherein 28 days is a treatment course and 3 treatment courses are continuously used.
The curative effect standard is as follows: 1. and (3) healing: disappearance of symptoms; 2. the effect is shown: the symptom is resolved by more than 50%; 3. the method has the following advantages: the symptom is resolved by more than 10%; 4. and (4) invalidation: no change before and after use.
The results of use are shown in table 1 below:
TABLE 1
While the embodiments of the present invention have been disclosed above, it is not limited to the applications listed in the description and embodiments, but is fully applicable to various fields suitable for the present invention, and it will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in the embodiments without departing from the principle and spirit of the present invention, and therefore the present invention is not limited to the specific details without departing from the general concept defined in the claims and the scope of equivalents thereof.
Claims (10)
1. An array of microspheres, comprising: the skin repairing carrier comprises a carrier, wherein microspheres are carried on the carrier, bioactive factors are filled in the microspheres, and the bioactive factors are used for repairing skin.
2. The microsphere array of claim 1, wherein: the microspheres are distributed and arranged on the carrier in a random or ordered form.
3. The microsphere array of claim 1, wherein the bioactive factor is EGF, basic fibroblast growth factor, transforming growth factor- β, platelet derived growth factor, interleukin 2, and interleukin 10.
4. The microsphere array according to claim 3, wherein the percentage content ratio of EGF, basic fibroblast growth factor, transforming growth factor- β, platelet-derived growth factor, interleukin 2 and interleukin 10 is 35:25:17:19:2: 2.
5. The microsphere array of claim 1, wherein: the particle size of the microsphere is 5-15 μm.
6. The microsphere array of claim 1, wherein: the concentration of the microspheres on the carrier is 50000-100000/cm2。
7. The microsphere array of claim 1, wherein: the carrier is non-woven fabric.
8. A method of preparing an array of microspheres according to any one of claims 1 to 7 wherein: the microspheres are immobilized on the surface of the carrier through physical action.
9. The method of claim 8, wherein: the microsphere is prepared by the following method:
(1) dissolving hyaluronic acid in water to obtain 5-9% solution;
(2) adding polyethylene glycol, glycerol and tween 80 into the solution in the step (1) under the condition of stirring, wherein the volume percentage of the polyethylene glycol, the glycerol and the tween 80 is 45:35:25, and uniformly mixing;
(3) spray drying to obtain 5-15 μm spheres;
(4) and (3) adding the mixed aqueous solution of the EGF, the basic fibroblast growth factor, the transforming growth factor- β, the platelet-derived growth factor, the interleukin 2 and the interleukin 10 which are obtained in proportion into the microspheres prepared in the step (3), and quickly stirring the microspheres at the stirring speed of 800-1200 rpm.
10. Use of an array of microspheres according to claim 1 for the preparation of a medicament or a skin care product for the repair of skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911200094.6A CN110960513A (en) | 2019-11-29 | 2019-11-29 | Microsphere array and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911200094.6A CN110960513A (en) | 2019-11-29 | 2019-11-29 | Microsphere array and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110960513A true CN110960513A (en) | 2020-04-07 |
Family
ID=70032089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911200094.6A Withdrawn CN110960513A (en) | 2019-11-29 | 2019-11-29 | Microsphere array and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110960513A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870148A (en) * | 2021-01-18 | 2021-06-01 | 广东轻工职业技术学院 | Preparation method of probiotics microsphere with microecological balance based on traction structure |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830507A (en) * | 1992-05-18 | 1998-11-03 | National Research Council Of Canada | Biotherapeutic cell-coated microspheres |
US20110244006A1 (en) * | 2007-11-29 | 2011-10-06 | The Trustees Of Columbia University In The City Of New York | Microsphere skin treatment |
CN110478517A (en) * | 2019-08-12 | 2019-11-22 | 南昌大学第一附属医院 | A kind of loading nano silvery and the medical dressing of bioactie agent and preparation method thereof |
-
2019
- 2019-11-29 CN CN201911200094.6A patent/CN110960513A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830507A (en) * | 1992-05-18 | 1998-11-03 | National Research Council Of Canada | Biotherapeutic cell-coated microspheres |
US20110244006A1 (en) * | 2007-11-29 | 2011-10-06 | The Trustees Of Columbia University In The City Of New York | Microsphere skin treatment |
CN110478517A (en) * | 2019-08-12 | 2019-11-22 | 南昌大学第一附属医院 | A kind of loading nano silvery and the medical dressing of bioactie agent and preparation method thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870148A (en) * | 2021-01-18 | 2021-06-01 | 广东轻工职业技术学院 | Preparation method of probiotics microsphere with microecological balance based on traction structure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101678621B1 (en) | Composition comprising spicules for skin care | |
AU2003270690B2 (en) | Lactoferrin compositions and methods of wound treatment | |
Cho et al. | Injectable biomaterials in plastic and reconstructive surgery: a review of the current status | |
EP2510980A1 (en) | A method for the dermocosmetic treatment of skin by application of NGF-containing compositions | |
CN108578747A (en) | A kind of gradient hyaluronic acid dressing and preparation method thereof | |
Jorgensen et al. | Advances in skin tissue engineering and regenerative medicine | |
CN104921983A (en) | Medical biological repairing dressing for pregnant woman striae gravidarum and preparation method thereof | |
CN108686255A (en) | It is a kind of to prevent the biological dressing and preparation method thereof that scar is formed | |
KR20180134468A (en) | Cosmetic compositions comprising spicule, marine collagen and deep ocean water and their preparation | |
Huang et al. | Combination therapy of hydrogel and stem cells for diabetic wound healing | |
Balavigneswaran et al. | Tissue engineered skin substitutes: A comprehensive review of basic design, fabrication using 3D printing, recent advances and challenges | |
EP2640409A1 (en) | A synergistic composition of plant extracts for treating skin diseases involving abnormal cell growth | |
CN103212108A (en) | Collagen wound healing film and preparation method thereof | |
Bian et al. | Basic fibroblast growth factor combined with extracellular matrix-inspired mimetic systems for effective skin regeneration and wound healing | |
CN110960513A (en) | Microsphere array and preparation method and application thereof | |
Mukherjee et al. | Silk fibroin and silk sericin in skin tissue engineering and wound healing: Retrospect and prospects | |
CN103550126A (en) | Biological acne-removing and scar-lightening repairing emulsion | |
CN103690393B (en) | Skin-whitening anti-wrinkle biological silk mask | |
CN114010579A (en) | Soluble anti-inflammatory repair microneedle and preparation method thereof | |
Naves et al. | Nanofiber composites in skin tissue engineering | |
CN103520708A (en) | Composition capable of promoting wound healing and reducing scarring | |
CN103751768A (en) | Preparation helping to heal wound | |
CN111228132A (en) | Skin composite preparation | |
CN102861320B (en) | Spray for treating skin and mucosa wounds | |
KR20180053601A (en) | Composition comprising growth factors and cytokines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200407 |
|
WW01 | Invention patent application withdrawn after publication |